U-Chart Analysis:Fuji Pharma Co.,Ltd.:4554

※The values of financial statements might be different from the actual ones. Please confirm the original. [instructions]

Main FunctionHelp Company NameHelp CodeHelp Types of IndustryHelp Market Name Fiscal Year End Year of Listing
Browse U-Chart Add to 'Companies Comparison' list Compare Lustrum Ullet index Fuji Pharma Co.,Ltd. Go to web site 4554 Medicals 東証プライム September 1, 2000 1995.
Analysis u.gifU-Chart AnalysisHelp hikaku.gifAdd to 'Companies Comparison' listHelp u2.gifCompare LustrumHelp mark.gifUllet indexHelp
Accounts Information Balance Sheet Profit and Loss Account Cash Flow Statement
Display

Fuji Pharma Co.,Ltd. Balance Sheet(B/S)

[Show - Hide] U-Chart:Balance Sheet (B/S)Help Icon

【Left:Outgoing Money】 【Right:Incoming Money】

Fuji Pharma Co.,Ltd. Balance Sheet 2023年9月期 Fuji Pharma Co.,Ltd. Balance Sheet 2022年9月期 Fuji Pharma Co.,Ltd. Balance Sheet 2021年9月期 Fuji Pharma Co.,Ltd. Balance Sheet 2020年9月期 Fuji Pharma Co.,Ltd. Balance Sheet 2019年9月期

[Show - Hide] Balance Sheet (B/S)Help  ※Unit:Millions of Yen

Accounting Date September 30, 2023 September 30, 2022 September 30, 2021 September 30, 2020 September 30, 2019
Cash and Cash Equivalents 2,324 3,546 10,199 12,041 8,494
Other Current AssetsHelp 36,790 31,181 24,635 22,934 25,425
Tangible Fixed AssetsHelp 20,547 18,762 14,392 12,767 11,718
Intangible Fixed AssetHelp 738 660 1,532 1,755 1,806
Investments and OthersHelp 15,178 11,645 12,616 11,321 11,800
Total AssetsHelp 85,332 75,538 64,239 61,962 60,737
Total Current LiabilitiesHelp 32,119 26,282 22,418 12,969 13,832
Total Long-term LiabilitiesHelp 12,038 13,452 9,141 9,034 7,544
Shareholder's EquityHelp 41,175 35,804 32,680 39,959 39,361
Total LiabilitiesHelp 85,332 75,538 64,239 61,962 60,737

Fuji Pharma Co.,Ltd. Profit and Loss Account(P/L)

[表示非表示] U-Chart:Profit and Loss Account (P/L)Help Icon

【Left:Outgoing Money】 【Right:Incoming Money】

Fuji Pharma Co.,Ltd. Profit and Loss Account 2023年9月期 Fuji Pharma Co.,Ltd. Profit and Loss Account 2022年9月期 Fuji Pharma Co.,Ltd. Profit and Loss Account 2021年9月期 Fuji Pharma Co.,Ltd. Profit and Loss Account 2020年9月期 Fuji Pharma Co.,Ltd. Profit and Loss Account 2019年9月期

[Show - Hide] Profit and Loss Account (P/L)Help  ※Unit:Millions of Yen

Accounting Date September 30, 2023 September 30, 2022 September 30, 2021 September 30, 2020 September 30, 2019
Amount of Sales 40,889 35,426 33,990 33,793 36,279
Total Sales 40,889 35,426 33,990 33,793 36,279
Cost of SalesHelp 24,374 20,867 19,239 18,921 20,483
Other Costs and RevenueHelp 13,079 11,862 12,318 12,786 12,833
Total CostsHelp 37,453 32,729 31,557 31,707 33,316
Net RevenueHelp 16,515 14,559 14,751 14,872 15,796
Earnings Before TaxHelp 4,399 3,723 3,371 2,918 3,961
Net IncomeHelp 3,436 2,697 2,433 2,086 2,963
Net Income 3,436 2,697 2,433 2,086 2,963

Fuji Pharma Co.,Ltd. Cash Flow Statement(C/F)

[表示非表示] U-Chart:Cash Flow Statement (C/F)Help Icon

【Left:Outgoing Money】 【Right:Incoming Money】

Fuji Pharma Co.,Ltd. Cash Flow Statement 2023年9月期 Fuji Pharma Co.,Ltd. Cash Flow Statement 2022年9月期 Fuji Pharma Co.,Ltd. Cash Flow Statement 2021年9月期 Fuji Pharma Co.,Ltd. Cash Flow Statement 2020年9月期 Fuji Pharma Co.,Ltd. Cash Flow Statement 2019年9月期

[Show - Hide] Cash Flow Statement (C/F)Help  ※Unit:Millions of Yen

Accounting Date September 30, 2023 September 30, 2022 September 30, 2021 September 30, 2020 September 30, 2019
Operating Cash Flow(OFC)Help 1,919 -659 5,993 5,769 7,034
Investing Cash Flow(ICF)Help -5,240 -11,271 -2,345 -2,616 -12,024
Financing Cash FlowHelp 1,915 5,094 -5,435 450 7,265
Exchange Difference of Cash and Cash EquivalentsHelp 185 183 -55 -56 -32
Net Increase and Decrease in Cash and Cash Equivalentsn -1,221 -6,653 -1,842 3,547 2,243

他社比較Help

Companies in 'Companies Comparison' list

Browsing historyHelp

Your reecently viewed companies

Fuji Pharma Co.,Ltd.

Company where related level is highHelp

Cuorips Inc.
Takeda Pharmaceutical Company Limited
SEIKAGAKU CORPORATION
Shionogi & Co.,Ltd.
HISAMITSU PHARMACEUTICAL CO.,INC.
Nissui Pharmaceutical Co.,Ltd.
D.Western Therapeutics Institute, Inc.
Tsubota Laboratory Incorporated
RIBOMIC Inc.
KYORIN Pharmaceutical Co., Ltd.